Cost-Benefit Of Early Access To NSCLC Drugs Evaluated In JAMA Study
Executive Summary
Researchers from University of California and Novartis present a framework for evaluating the social benefits of early access to new treatments on the basis of progression-free survival.
You may also be interested in...
Farydak Confirmatory Trial To Come Years After Accelerated Approval
Despite the agency’s preference that confirmatory trials generally be under way at the time of accelerated approval, Novartis’ panobinostat Phase III trial isn’t expected to begin for approximately three years.
Novartis’ Zykadia Sets New “Breakthrough” Speed Record For NME Review
FDA grants accelerated approval to ceritinib following a four-month review. The ALK inhibitor is indicated for non-small cell lung cancer patients who have progressed on or are intolerant of Pfizer’s Xalkori.
BIO’s New CEO Is Biotech Industry Veteran With Compelling Family Story, Ready To Take On The IRA
John Crowley will take the reins at BIO in March, about a year and a half after the departure of former CEO Michelle McMurry-Heath was announced.